1st Quarter - Report

VIR BIOTECHNOLOGY, INC. for VIR BIOTECHNOLOGY, INC.

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

COVID-19 Trade Related Aspects of Intellectual Property Rights Waiver

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Natl Security Council (NSC); SENATE; HOUSE OF REPRESENTATIVES; White House Office; U.S. International Trade Commission (ITC)

Health Issues HCR

Pandemic Preparedness Funding, Influenza Preparedness; COVID-19 Response and Therapeutics Procurement and Distribution; FY 2024 Labor-HHS Appropriations; Pandemic and All-Hazards Preparedness Act Reauthorization

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Health & Human Services, Dept of (HHS); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC)

Science/Technology SCI

Emergency Clinical Trials Policy; Pandemic Preparedness; Biomanufacturing

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Office of Science & Technology Policy (OSTP); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Inflation Reduction Act Rx Provisions Implementation

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

S. 866, American Innovation and Jobs Act

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 866 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.